Whisstock J, Lesk A M, Carrell R
Department of Haematology, Medical Research Council Centre, Cambridge, United Kingdom.
Proteins. 1996 Nov;26(3):288-303. doi: 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A.
Based on the most recent available crystal structures and biochemical studies of protease complexes of normal and mutant serine protease inhibitors (serpins), we have built models of the complexes: alpha 1-antitrypsin + human neutrophil elastase; alpha 1-antitrypsin Pittsburgh (358Met-->Arg) (Scott et al., J. Clin. Invest. 77:631-634, 1986) + tyrpsin; alpha 1-antitrypsin Pittsburgh (358Met-->Arg) + thrombin; and antithrombin + thrombin. All serpin sequences correspond to human molecules. The models show correct stereochemistry and no steric clashes between protease and inhibitor. The main structural differences in the serpins from the parent structures are: (1) the reactive center loop is inserted into the A-sheet as far as P12; (2) strand s1C is removed from the C-sheet; and (3) the C-terminus has changed conformation and interacts with the protease. In the absence of an X-ray structure determination of a serpin-protease complex, the demonstration that insertion of the reactive center loop into the A-sheet as far as P12 is stereochemically feasible provides structures of a protease-bound conformation of intact serpins with which to rationalize the properties of mutants, guide the design of experiments, and form a basis for further modeling studies, such as the investigation of the interaction of heparin with serpin-protease complexes.
基于正常和突变丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制因子,serpins)蛋白酶复合物的最新晶体结构及生化研究,我们构建了以下复合物模型:α1-抗胰蛋白酶+人中性粒细胞弹性蛋白酶;匹兹堡α1-抗胰蛋白酶(358位甲硫氨酸→精氨酸)(斯科特等人,《临床研究杂志》77:631 - 634, 1986)+胰蛋白酶;匹兹堡α1-抗胰蛋白酶(358位甲硫氨酸→精氨酸)+凝血酶;以及抗凝血酶+凝血酶。所有丝氨酸蛋白酶抑制因子序列均对应人类分子。这些模型显示出正确的立体化学结构,且蛋白酶与抑制剂之间不存在空间冲突。与亲本结构相比,丝氨酸蛋白酶抑制因子的主要结构差异在于:(1)反应中心环插入A片层直至P12;(2)s1C链从C片层移除;(3)C末端构象发生改变并与蛋白酶相互作用。在缺乏丝氨酸蛋白酶抑制因子-蛋白酶复合物的X射线结构测定的情况下,反应中心环插入A片层直至P12在立体化学上可行这一证明,提供了完整丝氨酸蛋白酶抑制因子与蛋白酶结合构象的结构,可据此解释突变体的特性、指导实验设计,并为进一步的建模研究(如研究肝素与丝氨酸蛋白酶抑制因子-蛋白酶复合物的相互作用)奠定基础。